[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582980":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":44,"responsibleParty":59,"collaborators":41,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":41,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":41,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":41,"overallStatus":84,"whyStopped":41,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Propranolol group","EXPERIMENTAL","This group Will receive propranolol intravenously at a dose of 1 mg every 6 h for 7 days.",[13],"Drug: propranolol",{"label":15,"type":16,"description":17,"interventionNames":18},"normal saline IV group","PLACEBO_COMPARATOR","This group Will receive 1ml of sterile 0.9% normal saline IV every 6 hours for 7 days",[19],"Drug: normal saline IV",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","propranolol","This group Will receive propranolol intravenously at a dose of 1 mg every 6 h for 7 days, and doses will be held if heart rate less than 60 bpm, mean arterial pressure less than 65 mmHg",[9],[27],"Experimental group",{"type":22,"name":29,"description":17,"armGroupLabels":30,"otherNames":31},"normal saline IV",[15],[32],"control group",[34],{"name":35,"affiliation":5,"role":36},"Huda Elkallaf, Resident","PRINCIPAL_INVESTIGATOR",[38,43],{"name":35,"role":39,"phone":40,"phoneExt":41,"email":42},"CONTACT","022 0 10 96213750",null,"hoda171661_pg@med.tanta.edu.eg",{"name":35,"role":39,"phone":41,"phoneExt":41,"email":41},[45],{"facility":5,"status":41,"city":46,"state":41,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Tanta","31527","Egypt","EG",{"type":51,"coordinates":52},"Point",[53,54],31.00192,30.78847,{"lat":54,"lon":53},[57],{"name":35,"role":39,"phone":58,"phoneExt":41,"email":42},"+20 10 96213750",{"type":36,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":41,"oldOrganization":41},"Huda Talaat Ibrahim Elkallaf","Resident of Emergency Medicine and Traumatology","100582980","phase-3-role-of-non-selective-beta-adrenergic-blocker-in-severe-tbi-100582980",false,"NCT06870370","Role of Non-Selective Beta-Adrenergic Blocker in Severe TBI","Role of Non-Selective Beta-Adrenergic Blocker in Severe Traumatic Brain Injury","Inclusion Criteria:\n\n* Patients aged between 18and 65 years old\n* Patients who have Severe traumatic brain injury\n* Glascow outcome scale ≤ 8\n\nExclusion Criteria:\n\n* Patients have pre-existing heart disease.\n* If there are contraindications to β blocker.\n* penetrating traumatic brain injury.\n* pre-injury brain dysfunction.\n* β-blocker or α2-agonist use before trauma.","ALL","18 Years","65 Years",{"count":73,"type":74},60,"ESTIMATED","INTERVENTIONAL",[77],"PHASE3","The role of nonselective beta adrenergic blocker as antistress agent in severe traumatic brain injury",[80,81,82,83],"Traumatic Brain Injury (TBI) Patients","Intracranial Pressure","Intensive Care Unit","Mortality","NOT_YET_RECRUITING","2025-03-06",{"date":87,"type":88},"2025-03-11","ACTUAL",{"date":90,"type":74},"2025-09-20",{"date":90,"type":74},{"name":5,"class":6},1]